AstraZeneca (LON:AZN) had its price objective lifted by investment analysts at DZ Bank from GBX 7,300 ($89.84) to GBX 7,500 ($92.30) in a report released on Friday, ThisIsMoney.Co.Uk reports. The firm currently has a “sell” rating on the biopharmaceutical company’s stock. DZ Bank’s price objective suggests a potential downside of 12.08% from the company’s previous close.
Several other research analysts also recently issued reports on AZN. UBS Group reissued a “sell” rating on shares of AstraZeneca in a research report on Monday, July 27th. Morgan Stanley reissued an “equal weight” rating and set a GBX 9,000 ($110.76) price objective on shares of AstraZeneca in a research report on Tuesday, July 21st. Barclays raised their price objective on shares of AstraZeneca from GBX 9,200 ($113.22) to GBX 9,300 ($114.45) and gave the stock an “overweight” rating in a research report on Wednesday. Credit Suisse Group restated an “outperform” rating on shares of AstraZeneca in a research note on Wednesday. Finally, Goldman Sachs Group set a GBX 6,000 ($73.84) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, July 28th. Six equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of GBX 8,347.78 ($102.73).
Shares of AstraZeneca stock opened at GBX 8,530 ($104.97) on Friday. AstraZeneca has a 1 year low of GBX 83.80 ($1.03) and a 1 year high of GBX 9,537.09 ($117.37). The company has a debt-to-equity ratio of 171.72, a quick ratio of 0.56 and a current ratio of 0.75. The company has a market capitalization of $111.94 billion and a P/E ratio of 73.73. The company’s fifty day moving average is GBX 8,583.32 and its two-hundred day moving average is GBX 7,938.56.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Determine Your Level of Risk Tolerance
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.